| 000 | 01418 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517200219.0 | ||
| 264 | 0 | _c20190715 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1752-8062 | ||
| 024 | 7 |
_a10.1111/cts.12540 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJi, Yan | |
| 245 | 0 | 0 |
_aChallenges and Opportunities in Dose Finding in Oncology and Immuno-oncology. _h[electronic resource] |
| 260 |
_bClinical and translational science _c07 2018 |
||
| 300 |
_a345-351 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadministration & dosage |
| 650 | 0 | 4 |
_aClinical Trials, Phase II as Topic _xstandards |
| 650 | 0 | 4 |
_aClinical Trials, Phase III as Topic _xstandards |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Development _xstandards |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 |
_aMedical Oncology _xstandards |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xstandards |
| 700 | 1 | _aJin, Jin Y | |
| 700 | 1 | _aHyman, David M | |
| 700 | 1 | _aKim, Geoffrey | |
| 700 | 1 | _aSuri, Ajit | |
| 773 | 0 |
_tClinical and translational science _gvol. 11 _gno. 4 _gp. 345-351 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/cts.12540 _zAvailable from publisher's website |
| 999 |
_c28036512 _d28036512 |
||